Weifa ASA is pleased to announce the launch of Solvivo® lozenges.
With Solvivo® Weifa enters the OTC throat segment, which has had a value growth of 64% last twelve months1, and represents a value of MNOK 11 last twelve months2 (pharmacy purchasing price). This is the fastest growing segment within the Cough & Cold3 category.
“Solvivo® is a strong fit with Weifa`s product portfolio, as well as the company`s ambitious strategy for the Cough and Cold category”, says CEO Kathrine Gamborg Andreassen. “The launch is set to strengthen Weifa`s current position as the fastest growing player within Cough & Cold.”
The launch will be supported by a solid communications campaign towards the end user, as well as a strong effort in training pharmacy staff.
Solvivo® is indicated for local symptomatic relief of mild mouth and throat infections in adults and children aged over 6 years. It contains the two active substances amylmetacresol and dichlorobenzyl alcohol, which have antiseptic properties. The product also provides a relieving effect on a sore throat and on difficulty in swallowing.
Similar products associated with strong commercial success can be found in many other countries; however, there are no identical products to Solvivo® on the Norwegian market.
Solvivo® comes in packs of 24 lozenges, in flavours of Honey & Lemon and Mint. It will be available through all pharmacy chains from September 15th 2016.
For further information, please contact:
Kathrine Gamborg Andreassen
+47 95 17 86 80, email@example.com
+47 98 20 63 55, firstname.lastname@example.org
Ref: 1,2,3,4: Farmastat September, 2016.
Barn under 6 år skal ikke ta dette legemidlet. Kontakt lege dersom symptomene ikke bedres innen 2 dager. Skal ikke brukes under graviditet og amming. Les pakningsvedlegget nøye før bruk.
Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no